💊 医薬品 A-Z 🧬 標的 🛠 ツール 📚 ガイド
全医薬品 薬物分類 治療領域 副作用
ガイド 用語集 年表
比較 薬物の体内の旅 薬物ファミリー
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Tapinarof

CHEMBL259571 Phase 4 承認済み Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
254.3 g/mol
LogP
4.6
Phase
4

Tapinarof is a first-in-class therapeutic aryl hydrocarbon receptor (AhR) agonist approved for the topical treatment of plaque psoriasis and atopic dermatitis in adults. By activating AhR, it normalizes skin barrier function, reduces pro-inflammatory cytokine production (including IL-17A, IL-22, and Th2 cytokines), and exerts antioxidant effects. Its non-steroidal mechanism offers an alternative to topical corticosteroids without the risk of skin atrophy.

分子量

254.3200 g/mol

LogP

4.60

TPSA

40.50 Ų

リピンスキーの五則

適合

治療領域

Psoriasis Systemic Lupus Erythematosus Atopic Dermatitis

作用機序

Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

機序

Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.

2D構造

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
CC(C)c1c(O)cc(/C=C/c2ccccc2)cc1O

                

                

                
                

                    
InChI

                    
InChI=1S/C17H18O2/c1-12(2)17-15(18)10-14(11-16(17)19)9-8-13-6-4-3-5-7-13/h3-12,18-19H,1-2H3/b9-8+

                

                

                

                    
                    

                        
Molecular Formula

                        
C17H18O2

                    

                    
                    

                        
HBD / HBA

                        
2 / 2

                    

                    
                    

                        
回転可能結合数

                        
3

                    

                    
                    
                    

                        
重原子数

                        
19

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
よくある質問

                

                    
                    

                        
                        

                            
Tapinarof is a first-in-class therapeutic aryl hydrocarbon receptor (AhR) agonist approved for the topical treatment of plaque psoriasis and atopic dermatitis in adults. By activating AhR, it normalizes skin barrier function, reduces pro-inflammatory cytokine production (including IL-17A, IL-22, and Th2 cytokines), and exerts antioxidant effects. Its non-steroidal mechanism offers an alternative to topical corticosteroids without the risk of skin atrophy.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.

                        

                    

                    

                    

                    

                        
                        

                            
Yes, Tapinarof is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL259571.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 6439522.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.




        


        
        
    


    



    
医学的免責事項

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.